The value of erlotinib related target molecules in kidney renal cell carcinoma via bioinformatics analysis

YunQiang Zhang1, MingYang Tang2, Qiang Guo3

  • 1Department of Thoracic Surgery, Beilun District people's Hospital of Ningbo, Ningbo, Zhejiang 315800, China.

Gene
|January 13, 2022
PubMed
Abstract

Insights

Erlotinib shows promise for metastatic kidney renal cell carcinoma (KIRC). Bioinformatics identified key genes (COL11A1, EMCN, etc.) linked to KIRC prognosis and immune infiltration, aiding in risk assessment.

Area of Science:

  • Oncology
  • Bioinformatics
  • Genomics

Background:

  • Erlotinib is an effective treatment for metastatic kidney renal cell carcinoma (KIRC).
  • Understanding erlotinib's molecular targets is crucial for improving KIRC treatment strategies.
  • Bioinformatic approaches can identify novel biomarkers for cancer prognosis.

Purpose of the Study:

  • To explore the prognostic value of erlotinib's target molecules in kidney renal cell carcinoma (KIRC).
  • To identify key genes associated with patient outcomes and immune infiltration in KIRC.
  • To develop a predictive model for KIRC prognosis based on erlotinib's molecular targets.

Main Methods:

  • Differential gene expression analysis of GSE25698 dataset after erlotinib treatment.
  • Functional enrichment analysis of differentially expressed genes (DEGs).
  • Construction of a prognostic risk model and nomogram using TCGA database and DEG analysis.

Main Results:

  • DEGs after erlotinib treatment were involved in antigen binding, myeloid cell activation, and JAK-STAT signaling.
  • Ten genes (COL11A1, EMCN, GLYATL1, HHLA2, IGFN1, LIPA, LRRC19, PANK1, PRAME, TNFSF14) were independent predictors of poor KIRC prognosis.
  • The risk score correlated with immune cell infiltration (e.g., regulatory T cells, M0 macrophages) and various signaling pathways (e.g., MAPK, apoptosis).

Conclusions:

  • The identified genes (COL11A1, EMCN, etc.) are significantly associated with KIRC prognosis and immune infiltration.
  • A risk model and nomogram incorporating erlotinib's target molecules can aid in evaluating KIRC patient prognosis.
  • These findings provide a basis for personalized treatment strategies in KIRC.